Amicus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Amicus Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 60.9% bzw. 21.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 60.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 20.6% betragen.

Wichtige Informationen

60.9%

Wachstumsrate der Gewinne

60.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	21.7%
Zukünftige Eigenkapitalrendite	20.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	30 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Jun 06

Amicus Therapeutics: Too Cheap At Under $10 A Share

May 20

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Mar 27

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

May 14

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Mar 23

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Dec 06

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Aug 25

Amicus Therapeutics: AT-GAA Approval Delayed, I Will Continue Holding

Aug 10

Amicus Therapeutics Q2 2022 Earnings Preview

Aug 03

Is Amicus Therapeutics (NASDAQ:FOLD) Weighed On By Its Debt Load?

May 06

Amicus Therapeutics: An Inflection Point In Growth

Apr 27

Amicus: July 29 PDUFA Makes It A Hold

Apr 11

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:FOLD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	841	211	278	265	6
12/31/2025	642	65	207	203	12
12/31/2024	510	-65	5	7	12
3/31/2024	423	-147	-88	-81	N/A
12/31/2023	399	-152	-77	-69	N/A
9/30/2023	372	-174	-162	-153	N/A
6/30/2023	351	-185	-133	-127	N/A
3/31/2023	337	-204	-131	-126	N/A
12/31/2022	329	-237	-170	-167	N/A
9/30/2022	323	-264	-159	-156	N/A
6/30/2022	321	-281	-172	-168	N/A
3/31/2022	318	-270	-192	-188	N/A
12/31/2021	306	-250	-206	-202	N/A
9/30/2021	294	-239	-185	-182	N/A
6/30/2021	282	-252	-203	-200	N/A
3/31/2021	267	-254	-201	-198	N/A
12/31/2020	261	-277	-237	-233	N/A
9/30/2020	246	-295	-254	-241	N/A
6/30/2020	227	-293	-272	-255	N/A
3/31/2020	209	-325	-298	-280	N/A
12/31/2019	182	-356	-270	-250	N/A
9/30/2019	160	-345	-264	-253	N/A
6/30/2019	131	-442	-340	-330	N/A
3/31/2019	109	-419	-337	-329	N/A
12/31/2018	91	-349	-306	-300	N/A
9/30/2018	73	-340	-318	-312	N/A
6/30/2018	64	-293	-233	-228	N/A
3/31/2018	49	-279	-218	-213	N/A
12/31/2017	37	-284	N/A	-214	N/A
9/30/2017	25	-273	N/A	-173	N/A
6/30/2017	16	-208	N/A	-165	N/A
3/31/2017	9	-211	N/A	-155	N/A
12/31/2016	5	-200	N/A	-150	N/A
9/30/2016	2	-184	N/A	-154	N/A
6/30/2016	N/A	-175	N/A	-134	N/A
3/31/2016	N/A	-152	N/A	-124	N/A
12/31/2015	N/A	-132	N/A	-100	N/A
9/30/2015	N/A	-110	N/A	-79	N/A
6/30/2015	0	-90	N/A	-73	N/A
3/31/2015	1	-77	N/A	-62	N/A
12/31/2014	1	-69	N/A	-52	N/A
9/30/2014	2	-60	N/A	-45	N/A
6/30/2014	1	-57	N/A	-44	N/A
3/31/2014	1	-58	N/A	-42	N/A
12/31/2013	0	-60	N/A	-46	N/A
9/30/2013	0	-57	N/A	-45	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FOLD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: FOLD wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: FOLD wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: FOLDDie Einnahmen des Unternehmens (21.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: FOLDDie Einnahmen des Unternehmens (21.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: FOLDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (20.6%)

Amicus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall by 78%

Recent updates

Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt

Amicus Therapeutics: Too Cheap At Under $10 A Share

Forecast to breakeven in 2025

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2023)

Amicus Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus EPS estimates fall by 78%

Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall by 78%

Consensus EPS estimates fall from profit to US$0.0023 loss

Forecast breakeven date pushed back to 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough

Executive Chairman notifies of intention to sell stock

Full year 2023 earnings: EPS misses analyst expectations

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Amicus Therapeutics: Expect Improved Commercial Momentum In 2024

Executive Chairman notifies of intention to sell stock

Amicus Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Executive Chairman notifies of intention to sell stock

Price target increased by 7.4% to US$19.44

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Insufficient new directors

Insider notifies of intention to sell stock

Price target increased by 8.0% to US$19.33

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk

Amicus Therapeutics Announces Executive Changes

CEO, President & Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director notifies of intention to sell stock

Amicus Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Amicus Therapeutics, Inc. announced that it has received $29.999985 million in funding

Price target increased by 7.3% to US$17.60

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc. (NasdaqGM:FOLD).

Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Consensus estimates of losses per share improve by 11%

Chief Accounting Officer & Controller notifies of intention to sell stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer

CEO, President & Director notifies of intention to sell stock

Amicus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller

Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt

Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union

CEO, President & Director notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 23%

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

CEO, President & Director notifies of intention to sell stock

CEO, President & Director exercised options and sold US$103k worth of stock

Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 16%

CEO, President & Director exercised options and sold US$125k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Amicus Therapeutics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Executive Chairman notifies of intention to sell stock

Insider notifies of intention to sell stock

Independent Director exercised options and sold US$146k worth of stock

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Chief People Officer notifies of intention to sell stock

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

We Think Amicus Therapeutics (NASDAQ:FOLD) Has A Fair Chunk Of Debt

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind